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ments) and University of Arizona (UA) patients who were
treated in the hospital (n  27, 72 treatments). All
healthcare resources and treatment outcomes were ob-
tained for each episode of FN. Uniform charge values
were applied to each healthcare resource. Outcome data
included positive blood cultures and days to resolution of
FN, based upon fever and absolute neutrophil count. We
applied Mann-Whitney U and chi square tests. Sensitivity
analyses were performed using charges per episode. 
RESULTS: Both groups were similar for gender, age, types
of diseases, and FN-inducing chemotherapies. More of the
home-treated patients were treated with granulocyte colony
stimulating factor (58 versus 42, p  0.004). The median
total estimated charge per episode was $9166 for UA pa-
tients versus $5117 for UNM patients (p  0.001). Lower
charges for UNM patients, included hospital days, microbi-
ology cultures, blood counts, serum chemistries, physician
visits, radiologic studies, and serum antibiotic levels. Posi-
tive blood cultures occurred more frequently in UA patients
(30.6% versus 11.1%, p  0.012) and mean days to reso-
lution of FN was 8.6 versus 7.6 for UNM patients (NS).
Results were stable across all sensitivity analyses. 
CONCLUSION: With careful supervision by a pediatric
oncology center, uncomplicated FN can be treated by
home care, with substantial savings.
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Few studies have investigated the cost-effectiveness of
oral chemotherapeutic agents that are used to treat meta-
static breast cancer (MBC) at home and in clinic settings. 
OBJECTIVE: This study assessed the value of MBC man-
agement using intravenous (IV) and oral chemotherapeu-
tic agents. 
METHODS: A predictive data collection approach
(modeling) was used to perform this cost-effectiveness
analysis. Data were used from existing economic com-
parisons between home care and clinic care, from clinical
trials, and using Medicare cost data in 1998 US dollars.
A societal perspective was used to compare the cost-effec-
tiveness of the following first-line chemotherapy regi-
mens: C*MF (oral cyclophosphamide [C*], IV metho-
trexate [M], IV fluoruracil [F]), and AC (IV doxorubicin
[A] and IV cyclophosphamide) at home and at an outpa-
tient clinic; and the second-line regimens: IV paclitaxel
(P), oral etoposide (E*), oral idarubicin (I*), and oral
UFT (U*) at home and at an outpatient clinic. 
RESULTS: C*MF, administered at home, was the most
cost-effective first-line strategy (34,163 $/QALY). The
home AC regimen was more costly, and more effective. It
was not, however, cost-effective relative to the home
C*MF strategy because the incremental cost-effectiveness
(ICE) between the two strategies was 1,763,990 $/QALY.
E*, administered at home, was found to be the most cost-
effective second-line strategy (33,789 $/QALY). Other
strategies (home P, clinic I*, and home I*) were more
costly, but more effective. These strategies, however, were
not cost-effective relative to home E* because the ICE be-
tween these strategies and E* were 945,101 $/QALY,
369,232 $/QALY, and 175,523 $/QALY, respectively. 
CONCLUSIONS: These results suggest that oral chemo-
therapeutic agents, administered at home, provide a cost-
effective means of treating MBC.
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OBJECTIVE: This study was undertaken to determine the
optimal scoring for the Breast Evaluation Questionnaire
(BEQ), and to provide evidence for its validity as a mea-
sure of comfort and satisfaction for women undergoing
breast augmentation for cosmetic reasons. The BEQ is a
55-item questionnaire. A 76-item version was previously
validated in a sample of undergraduate women (non-clini-
cal sample). The BEQ measures satisfaction with breast at-
tributes, and comfort with general appearance and appear-
ance of breasts while fully dressed, in a bathing suit, and
while naked, across a variety of situations. 
METHODS: We conducted exploratory factor analysis in
1244 women at baseline prior to the augmentation proce-
dure. We conducted analysis of reliability of the factors, ex-
amined discriminant validity of the items of the BEQ, and
examined associations between the BEQ factors and widely
used measures of self-esteem and body-self relations. 
RESULTS: The factor analysis indicated that the BEQ is op-
timally scored as three factors: Comfort Not Fully Dressed,
Comfort Fully Dressed, and Satisfaction with Breast At-
tributes. These factors form internally consistent subscales,
which remain reliable over time (Cronbach’s  minimum
value across four visits was .89 for all three factors). We
demonstrated that the items have discriminant validity. The
factors are moderately correlated with the Appearance Eval-
uation subscale of the Multi-Dimensional Body Self Rela-
tions Questionnaire (MBSRQ) and the Physical Self sub-
scale of the Tennessee Self-Concept Scale (TSC). 
CONCLUSIONS: The BEQ can now be scored with
greater simplicity and greater ease of interpretation than
was previously indicated.
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